
    
      Patients who have

        -  completed 4 course of platinum/etoposide and thoracic radiotherapy of 45 Gy/30
           fractions, 2 fractions per day

        -  non-progression after chemo-radiotherapy

        -  ECOG performance status 0-2

      will be randomized to receive atezolizumab 1200 mg IV every 3 weeks in 12 months or standard
      of care (observation).
    
  